-
Product Insights
NewLeber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Drugs In Development, 2024
Empower your strategies with our Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) – Drugs In Development, 2024 report and make more profitable business decisions. Leber’s hereditary optic neuropathy (LHON) is an inherited form of vision loss. This condition usually begins in a person's teens or twenties; rare cases may appear in early childhood or later in adulthood. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling, and clouding of vision. Predisposing factors include age,...
-
Product Insights
NewPhelan-McDermid Syndrome (22q13.3 Deletion Syndrome) – Drugs In Development, 2024
Empower your strategies with our Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions. Phelan-McDermid syndrome, also called 22q13 deletion syndrome, is a genetic disorder caused by deletion of part of chromosome 22 or a defect in a gene called SHANK3. Symptoms can include intellectual disability, motor skill deficits, delayed or absent speech, autism spectrum disorder, and minor dysmorphic features. The Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) drugs in development market research report provide...
-
Product Insights
NewPolycystic Kidney Disease – Drugs In Development, 2024
Empower your strategies with our Polycystic Kidney Disease – Drugs In Development, 2024 report and make more profitable business decisions. Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. PKD symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination, and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. The Polycystic Kidney Disease drugs in development market research report provide...
-
Product Insights
NewRetinal Degeneration – Drugs In Development, 2024
Empower your strategies with our Retinal Degeneration – Drugs In Development, 2024 report and make more profitable business decisions. Retinal degeneration refers to a group of diseases that cause progressive damage to the cells of the retina, the light-sensitive tissue at the back of the eye crucial for vision. These conditions lead to a gradual loss of vision, which can range from mild to severe and can eventually result in blindness. There are several types of retinal degenerative diseases, including: Retinitis...
-
Product Insights
NewRetinitis Pigmentosa (Retinitis) – Drugs In Development, 2024
Empower your strategies with our Retinitis Pigmentosa (Retinitis) – Drugs In Development, 2024 report and make more profitable business decisions. Retinitis pigmentosa refers to a group of diseases that cause a slow but progressive loss of vision. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa (Retinitis) drugs in development market research report provide comprehensive information on...
-
Product Insights
NewChronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2024
Empower your strategies with our Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic myeloid leukemia (CML), also known as chronic myelocytic leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age, and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen, and pain or a...
-
Product Insights
NewDuchenne Muscular Dystrophy – Drugs In Development, 2024
Empower your strategies with our Duchenne Muscular Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. Risk factors include gender and family history. Treatments include steroid medication, respiratory therapy, and surgery. The Duchenne Muscular Dystrophy drugs in development market research report provide comprehensive information...
-
Product Insights
NewNeuroblastoma – Drugs In Development, 2024
Empower your strategies with our Neuroblastoma – Drugs In Development, 2024 report and make more profitable business decisions. Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest, or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands before spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include a lump in the abdomen or chest, weakness, bone pain, breathing problems, dark...
-
Product Insights
NewRecessive X Chromosome Disorders – Drugs In Development, 2024
Empower your strategies with our Recessive X Chromosome Disorders – Drugs In Development, 2024 report and make more profitable business decisions. A recessive X chromosome disorder, also known as an X-linked recessive disorder, is a genetic condition caused by a mutation on one of the X chromosomes, one of the two sex chromosomes. Typically, males have one X and one Y chromosome (XY), while females have two X chromosomes (XX). In recessive X-linked disorders, the mutated gene is located on the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VP-001 in Retinitis Pigmentosa (Retinitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VP-001 in Retinitis Pigmentosa (Retinitis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VP-001 in Retinitis Pigmentosa (Retinitis) Drug Details: VP-001 is under...